Increased plasma FFA reduce insulin-stimulated glucose uptake. The mechanisms responsible for this inhibition, however, remain uncertain. It was the aim of this study to determine whether the FFA effect was dose dependent and to investigate its mechanism. We have examined in healthy volunteers (13 male/1 female) the effects of three steady state plasma FFA levels ( -50, -550, -750 MuM) on rates of glucose uptake, glycolysis (both with 3-3H-glucose), glycogen synthesis (determined with two independent methods), carbohydrate (CHO) oxidation (by indirect calorimetry), hepatic glucose output, and nonoxidative glycolysis (glycolysis minus CHO oxidation) during euglycemic-hyperinsulinemic clamping. Increasing FFA concentration (from -50 to -750 gM) decreased glucose uptake in a dose-dependent fashion (from -9 to -4 mg/kg per min). The decrease was caused mainly (-2/3) by a reduction in glycogen synthesis and to a lesser extent ( 1/3) by a reduction in CHO oxidation. We have identified two independent defects in glycogen synthesis. The first consisted of an impairment of muscle glycogen synthase activity. It required high FFA concentration ( -750MM), was associated with an increase in glucose-6-phosphate, and developed after 4-6 h of fat infusion. The second defect, which preceded the glycogen synthase defect, was seen at medium ( -550MM) FFA concentration, was associated with a decrease in muscle glucose-6-phosphate concentration, and was probably due to a reduction in glucose transport/phosphorylation. In addition, FFA and/or glycerol increased insulin-suppressed hepatic glucose output by -50%. We concluded that fatty acids caused a dose-dependent inhibition of insulin-stimulated glucose uptake (by decreasing glycogen synthesis and CHO oxidation) and that FFA and/or glycerol increased insulin-suppressed hepatic glucose output and thus caused insulin resistance at the peripheral and the hepatic level. (J. Clin. Invest. 1994. 93:2438-2446
Introduction
Inability of insulin to appropriately promote glucose uptake in skeletal muscle (insulin resistance) has been recognized as an February 1994. early and prevalent abnormality in non-insulin-dependent diabetes mellitus (NIDDM)l (for review see reference 1). While its cause remains uncertain, insulin resistance is known to be commonly associated with an inability of insulin to normally promote nonoxidative glucose disposal (glucose storage) and to activate skeletal muscle glycogen synthase (GS) (2) (3) (4) (5) (6) (7) (8) (9) . There is evidence to suggest that in many instances the defects in glucose uptake and storage may be related to abnormal fat metabolism (10, 11) . First, most patients with NIDDM are obese and have elevated blood FFA concentrations (12) , which have been shown to inhibit insulin-stimulated glucose uptake (13) (14) (15) (16) (17) . The issue of whether or not FFA inhibit glucose uptake has remained somewhat controversial since some investigators have failed to find such an effect (18, 19) . We have demonstrated recently, however, that the fatty acid-mediated inhibition of insulin-stimulated glucose uptake only developed after 3-4 h of fat infusion ( 15 ) . It is therefore likely that insufficient length of fat infusion was the reason why the inhibitory effect of FFA on glucose uptake was not found in some studies. Second, Gulli et al. (20) have recently shown in offspring of parents with NIDDM, known to be at high risk to develop the disease (7, 8) , that impaired insulin-stimulated glucose uptake and storage were associated with elevated fatty acid levels and oxidation. Third, fat infusion has recently been shown to be associated with suppression of insulin-stimulated skeletal muscle GS activity ( 15, 16) . It was not clear from these studies, however, whether the observed GS defect was responsible for the inhibition ofglucose uptake. GS activities were measured only before and after but not during fat infusions; thus, it remained unknown whether the GS defect preceded, coincided with, or followed the inhibition in glucose uptake. Moreover, glycogen synthesis, which does not always correlate with GS activity (21 ) , was not measured. The aim of this study was therefore to determine whether the fatty acid effects were dose dependent and to elucidate their mechanisms by examining FFA actions on all major pathways ofintracellular glucose utilization. To 
Experimental design
Study I (highfatty acids). Four subjects were studied in this protocol. 3-3H-glucose was infused intravenously for 7.5 h (-90 to 360 min) starting with a bolus of 40 1Ci over 1 min, followed by a continuous infusion of0. 4 ,Ci/min. At 0 min, LIPOSYN II (Abbott Laboratories, North Chicago, IL) a 20% triglyceride emulsion (10% safflower, 10% soy bean oil) plus heparin (0.4 U/kg per min) were infused at a rate of 1.5 ml/min for 6 h. Regular human insulin (Humulin R; Eli Lilly & Co., Indianapolis, IN) was infused intravenously at a rate of 1 mU/kg per min for 6 h starting at 0 min. Glucose concentrations were clamped at -85 mg/dl by a feedback-controlled glucose infusion. The first muscle biopsy was performed before the start ofthe infusions (between -90 and 0 min), and the other three biopsies were performed at 120, 240, and 360 min, respectively. Study 2 (medium fatty acids). Four subjects were studied in this protocol, which was identical to study 1 except that LIPOSYN II was infused without heparin.
Study 3 (lowfatty acids). Six subjects were studied. All six received insulin and glucose as in studies 1 and 2. Three received, in addition, glycerol (0.7±0.05 mg/kg per min) plus heparin (0.4 U/kg per min) to simulate glycerol and heparin infusions in study 1 (LIPOSYN II contains 2.14 g glycerol/ 100 ml as emulsifier). The additional infusion of glycerol and heparin had no effect on any of the metabolic parameters measured including serum concentrations of glucose, insulin, and glucagon and rates ofglucose appearance, oxidation, glycolysis, and glycogen synthesis. The data from the studies with and without glycerol plus heparin were therefore combined.
Glucose turnover
Glucose turnover was determined with 3-3H-glucose. The tracer infusion was started 90 min before initiation of the clamp to assure isotope equilibration. Glucose was isolated from blood for determination of 3-3H-glucose specific activity as described (22) . Changes in specific activity during hyperinsulinemia were avoided by adding 3-3H-glucose to the unlabeled glucose, which was infused at variable rates to main- tain euglycemia (23) . Rates oftotal body glucose appearance and disappearance (GRd) were calculated using Steele's equation for steady state conditions (24) . As seen in Fig. 1 , serum 3-3H-glucose specific activities were at steady state for all three groups and for the entire length of the studies except for minor changes during the initial 90 min.
Glycolyticflux
Glycolytic flux was determined according to Rossetti and Giaccari with minor modifications (25) . Tritium in the 3-carbon position ofglucose is lost into water during glycolysis. Recently, we have validated the assumption that the rate ofplasma tritiated water formation reflects the intracellular detritiation of 3-3H-glucose (26). The rate of glycolysis was obtained by dividing the whole body 3H20 production rate by the specific activity of its precursor, i.e., plasma 3-3H-glucose. To calculate the 3H20 production rate, the time course of the plasma 3H20 concentration was plotted vs time, and the slope of the linear regression was estimated by the least square method. The whole body production rate was obtained by multiplying this value with the body water volume measured in each study subject. Total body water occupies -73% of fat free mass (FFM) (26). The latter was determined by underwater weighing (27) .
Glycogen synthesis
Glycogen synthesis was quantitated by two independent methods. First, because net glycogen synthesis is the portion of glucose flux not entering glycolysis, whole body glycogen synthesis rates were obtained by subtracting rates of glycolysis from rates of glucose uptake (GRd).
We have documented the validity of this noninvasive approach by demonstrating in healthy humans that results obtained with this method were comparable with rates of glycogen synthesis determined by incorporation of tritium from 3-3H-glucose into muscle glycogen. Second, rates of glycogen formation were calculated on the basis of in vitro muscle GS activity determined with actually measured muscle concentrations of glucose-6-phosphate (G-6-P) and uridine-diphosphate-glucose (UDPG) (26). Glycogen synthesis per unit muscle was extrapolated to whole body glycogen synthesis, assuming that 52% of FFM was muscle (26).
CHO and lipid oxidation CHO and lipid oxidation were determined by indirect calorimetry as described (28) with a metabolic measurement cart (Beckman Instruments, Inc., Palo Alto, CA). Rates of protein oxidation were estimated from urinary N excretion after correction for changes in urea N pool size (29) . Rates of protein oxidation were used to determine the nonprotein respiratory quotient (npRQ). It was assumed that for each gram of N excreted in the urine, 6.02 liters of 02 were consumed, and 4.75 liters of CO2 were produced (RQ = 0.79). Rates of CHO and fat oxidation were determined with the npRQ tables of Lusk, which are based on an npRQ of 0.707 for 100% fat oxidation and 1.00 for 100% CHO oxidation.
Muscle biopsies and extractions
Biopsies were obtained from the lateral aspect of the vastus lateralis muscle -15 cm above the patella from all subjects as described ( 15) . The excised muscle sample ( 150 mg) was dropped immediately into isopentane, kept at its freezing point (-160'C) by liquid nitrogen. The frozen muscle was stored at -80'C until it was aliquoted for measurement of GS, G-6-P/UDPG, and glycogen phosphorylase.
Metabolite assays
Muscle UDPG concentration was measured after two sequential chromatographic and HPLC separations and ultraviolet detection, as reported previously (26) . Briefly, the first is performed on a solid-phase, strong anion exchange cartridge, with the use of phosphate buffers of increasing molarity. This first purification allows one to partially separate the compound ofinterest from all nonpolar and most ofthe polar intracellular substrates with optimal recoveries. The second step is a reversed-phase, ion-pairing HPLC isocratic method on a C18T column (Supelco, Inc., Bellefonte, PA). Muscle G-6-P concentrations were measured spectrophotometrically as described by Michal (30) .
GS assay
Muscle GS activity was measured by a modification (31, 32) of the method of Thomas et al. (33) and is based on the measurement ofthe incorporation of radioactivity into glycogen from UDP-[U-14C1-glucose. Tissue samples (7-12 mg) were homogenized in 1.0 ml of Tris-HCl buffer, pH 7.8, containing 10 mM EDTA, 5 mM DTT, 50 mM NaF, and 2.5 g/liter rabbit liver glycogen type III. The homogenate was centrifuged at 2,000 g for 15 min (at 4°C), and the supernatant was used for the GS assay by measuring the incorporation ofUDP-[U-14C]glucose into glycogen at 37°C. For the kinetic analysis, the assay was conducted at final concentrations of 0.005, 0.025, 0.050, 0.125,0.50, and 2.0mM UDPG and 0,0.11,0.22, and 7.2 mM G-6-P; the data were linearized as Eadie-Hofstee plots and fit using linear regression. The Km for UDPG is the reciprocal ofthe slope, whereas the V. is the y-intercept divided by the slope.
GS activity was calculated as micromoles of UDPG incorporated into glycogen per minute per milligram ofprotein and was expressed as Km, the concentration of UDPG at which GS activity was half maximal, as V,.,, or as the fractional velocity ofGS activity, i.e., the activity ofGS at 0.1 mM G-6-P divided by the activity at 7.2 mM G-6-P. This is an indicator of the active form of GS and believed to be a sensitive parameter of in vivo GS activity (34) .
Glycogen phosphorylase assay
Muscle glycogen phosphorylase activity was measured as described previously (31 ). This assay is based on the measurement ofthe incorporation ofcarbon-14 into glycogen from labeled glucose 1-phosphate. Glycogen phosphorylase a, the active phosphorylated enzyme, was assayed in the absence ofAMP, and phosphorylase b, the total enzyme activity, was assayed in the presence of 5 mM AMP. The tissue homogenates (7) (8) (9) (10) (11) (12) 
Body composition
Body composition wasdetermined by underwaterweighing with correction for residual lung volume (27) , which was determined after immersion in a sitting position with a closed circuit°2 dilution method (27 
Results
Euglycemic insulin clamps with and withoutfat infusion (Fig.  2) . In all three studies, insulin infusion raised plasma insulin concentrations from -5 to -70 MuU/ml. Plasma glucose was clamped at -85 mg/dl. In the low fatty acid group, plasma FFA decreased from 526±90 before to 54±6MtM during insulin infusion. In the medium fatty acid group, FFA concentration was 500±120 before and 632±133 ,uM at the end ofthe clamp (NS). In the high fatty acid group, FFA concentrations increased from 415±69 before to 748±34 ,uM at the end of the clamp (P < 0.01). The three FFA concentration curves (high, medium, and low fatty acid groups) were significantly different from each other (overall comparison of groups by ANOVA with repeated measures P < 0.001 ).
Leg blood flow rates were 4.0±0.6, 3.8±0.5, and 3.9±0.3 ml/dl leg tissue per min in the low, medium, and high fatty acid groups, respectively. During insulin infusions, leg flow rates increased to 4.7±0.8, 5.7±0.9, and 5.7±0.9 ml/dl, respectively. The differences among the three groups were not statistically significant.
Glucose uptake (GRd) (Fig. 3, top) . GRd rose from -2 to -6 mg/kg per min during the initial 90 min of insulin infusion in all three groups. Thereafter, GRd in the low, medium, and high fatty acid groups were significantly different from each other (overall comparison of groups). GRd rose further to -9 mg/kg per min in the low fatty acid group, stabilized at -6 mg/kg per min in the medium fatty acid group, and declined to -4 mg/kg per min in the high fatty acid group. Comparing individual time points, the differences between high and low fatty acid groups became significant at 210 min.
Comparing mean values ofthe last 3 h (180-360 min) ( FFA concentrations over the entire range of FFA concentrations tested.
Glycogen synthesis (Fig. 3, middle Glycogen synthesis rates declined with increasing plasma FFA over the entire range of FFA concentrations tested (Fig. 4) .
Glycogen synthesis rates determined on the basis of muscle GS activities measured at in vivo G-6-P and UDPG concentrations yielded similar results. Basal rates of glycogen synthesis combining values from all three groups, however, were slightly higher than values obtained with the noninvasive subtraction method (1.0±0.2 vs 0.2±0.1 mg/kg per min). An inhibitory Whole body glucose determined on the basis of muscle GS measurements with in vivo G-6-P/UDPG concentrations (bottom) during euglycemic-hyperinsulinemic clamping at high (n = 4), medium (n = 4), and low FFA concentrations (n = 6). Shown are mean±SE. Symbols as in Fig. 1 effect of fatty acids was apparent at the first biopsy after start of the lipid infusions (2 h) and continued to be present until the end of the studies in the high but not the medium FFA groups (Fig. 3, bottom) . Glycolysis (Fig. 5, top (Fig. 4) .
Mechanisms ofFFA-induced Inhibition ofGlucose Uptake 2441 CHO oxidation (Fig. 5, middle) . Rates of CHO oxidation increased from 0.63±0.21 to 2.33±0.21 mg/kg per min (P < 0.01 ) in the low fatty acid group. In both medium and high fatty acid groups, CHO oxidation did not increase significantly above basal values during insulin infusions and remained lower than in the low fatty acid group. These differences became statistically significant at 150 min (P < 0.05).
CHO oxidation rates declined when plasma FFA increased from 51±5 to 562±106 ,uM (P < 0.01). There was no further decline in CHO oxidation rates when plasma FFA concentration increased from 562±106 to 766±44 ,uM (Fig. 4) . Nonoxidative glycolysis (Fig. 5, bottom) (Fig. 4) .
Muscle GS (Fig. 7) . The Km of GS activity (Fig. 7, top) declined significantly between 0 and 2 h in all three groups. In the low and medium fatty acid groups, Km remained low until the end of the studies. In the high fatty acid group, Km increased between 4 and 6 h and at 6 h had reached preclamp levels. GS V. (GS at 7.2 mM G-6-P) (Fig. 7, middle) , represent- ing an index of the total amount of enzyme present in muscle, was the same in all three groups and did not change significantly in response to insulin or to fatty acids.
GS fractional velocity (Fig. 7, bottom) , the ratio ofGS activities at 0.1 1 and 7.2 mM G-6-P, is considered a good indicator of in vivo enzyme activity. It increased significantly in all three groups in response to insulin between 0 and 4 h. Between 4 and 6 h GS fractional velocity remained elevated in the low and medium, but declined significantly in the high fatty acid group.
Muscle glycogen phosphorylase and G-6-P (Table II) . Glycogen phosphorylase a activities did not change significantly in response to insulin or to insulin plus fatty acids in any of the three groups.
There were no statistically significant changes in G-6-P concentrations in any of the three groups between 0 and 4 h. Between 4 and 6 h, G-6-P increased significantly in the high fatty acid group (P < 0.05), while it remained unchanged in the low and medium fatty acid groups.
Discussion
FFA/CHO metabolism dose effect relationships. In this study, we have examined effects ofthree steady state plasma fatty acid concentrations on the ability of insulin to promote glucose uptake and on the rate of intracellular glucose utilization, i.e., glycogen synthesis and glycolysis. As > 80% of the glucose infused intravenously has been shown to be taken up by muscle (42) , our results provided information primarily on the effects of FFA on muscle metabolism.
Boden, Chen, Ruiz, White, and Rossetti (Figs. 3 and 4) . Overall, the major part ( -2/3) of the decline in GRd was caused by reduction in the rate of glycogen synthesis, and a minor part ( -l/) was caused by reduction in the rate of CHO oxidation. The decrease in GRd of -3 mg/kg per min which occurred when FFA concentrations rose from -50 to -500 gM was accounted for equally by decreases in CHO oxidation and glycogen synthesis, while the decline in GRd which occurred when plasma FFA concentrations rose further (from -550 to -750 ,gM) was caused exclusively by a decrease in glycogen synthesis. These findings expanded earlier observations (13, 43) that the effect of fat on CHO oxidation was relatively small and that the main problem in obese diabetic and nondiabetic subjects, whose FFA concentrations are commonly > 500 OM, was a defect in nonoxidative glucose disposal (1) (2) (3) (4) (5) (6) (7) (8) (9) and muscle biopsy samples revealed, however, that glycogen synthesis was already inhibited before inhibition of muscle GS activity. This indicated the presence of an additional, earlier fatty acid-induced block ofglycogen synthesis which was unrelated to an impairment of GS. Glycogen synthesis depends primarily on the activity of the rate-limiting enzyme GS and the availability of its main substrate G-6-P/UDPG. The observed reduction of glycogen synthesis associated with normal GS activity, therefore, suggested that fatty acids had lowered G-6-P/UDPG levels in skeletal muscle. This suggestion was supported when rates ofglycogen synthesis were determined in vitro with in vivo G-6-P and UDPG concentrations (Fig. 3 Nonoxidativeglycolysis. Independent determination ofglycolysis and CHO oxidation allowed us to calculate rates of nonoxidative glycolysis, which consists essentially of lactate and alanine production rates. Our data suggested that neither insulin nor fat infusion affected nonoxidative glycolysis, which remained at 1-1.5 mg/kg per min during all three studies. These findings are in accord with those of Consoli et al. (47) who reported postabsorptive lactate and alanine production rates of -1.4 mg/kg per min in normal volunteers. They are also in agreement with data showing that insulin has little or no effect on lactate and alanine release from resting muscle ( 16, 48, 49) . Our data do not exclude a small increase in lactate accompanied by a decrease in alanine production in response to lipid infusion as has been observed by Kelley et al. ( 16) in arterio-venous balance studies across forearm muscle.
HGO. Confirming reports by others ( 14, 17, 50) , we found that lipid infusions interfered with insulin's suppressive effect on HGO, i.e., caused hepatic insulin resistance. The present study showed, in addition, that this effect appeared early and seemed greatest at postabsorptive FFA concentrations (~550,gM).
The mechanisms responsible for this effect were not studied but could have been related to elevated plasma concentrations of FFA, glycerol, or both. Lipolysis from the infused fat resulted in increased production of fatty acids and glycerol, resulting not only in higher FFA but also in higher glycerol concentrations (4.5±0.6 vs 3.8±0.2 vs 1.2±0.4 mg/dl, respectively, in high, medium, and low FFA studies). Putative mechanisms for the lipid effect on HGO include enhanced 1#-oxidation of fatty acids which provides ATP, i.e., the energy needed to drive gluconeogenesis, as well as acetyl-CoA which activates pyruvate carboxylase, the first key enzyme in the gluconeogenetic pathway ( 51 ), and increased availability of glycerol which is an excellent substrate for gluconeogenesis (52) .
Fatty acids and insulin clearance. Despite large differences in plasma FFA concentrations (from 50 to 750 ,uM), steady state serum insulin concentrations, produced by continuous infusion ofinsulin at a rate of 1 mU/kg per min, were the same in all three groups. These data do not support the hypothesis 2444 Boden, Chen, Ruiz, White, and Rossetti that elevated FFA concentrations interfere with hepatic degradation of insulin and thus are responsible, at least in part, for the hyperinsulinemia seen in obese diabetic and nondiabetic individuals (for review see reference 53).
Physiological relevance. Impaired insulin stimulation of glucose storage and GS activity and increased hepatic glucose production have been consistent findings in obese diabetic and nondiabetic individuals. The demonstration that FFA suppressed insulin-stimulated glucose uptake and that the products of lipolysis, i.e., FFA and glycerol, increased hepatic glucose production supported the notion that abnormal fat metabolism, perhaps superimposed on genetic abnormalities (7, 54, 55) , may account for much ofthe peripheral and hepatic insulin resistance of obese diabetic and nondiabetic subjects.
The observation that FFA inhibited glucose uptake in a dose-dependent fashion throughout the physiologic range of plasma FFA concentrations suggested further that for every lowering in plasma FFA, regardless of the ambient FFA level, there would be a corresponding decrease in insulin resistance. This could perhaps be exploited by treating insulin-resistant diabetic patients with antilipolytic agents.
